ASCO26 : LURBINECTEDIN 8 PRESENTACIÓNES (NADA DE LAGOON NI DE SALUDO). TARLATAMAB 27 PRESENTACIÓNES . //.....// . PharmaMar ha Actualizado en EEUU La FASE III SaLuDo Para el Tratamiento del Leiomiosarcoma . La Compañía Confirma Que el Estudio Sigue en FASE de Reclutamiento y Estimada su Finalización el 30-8-29 . Según su Presentación Corporativa de Abril 2026, el Ensayo se Encuentra Aproximadamente en la Mitad de su Desarrollo, lo Que Sugiere una Ejecución en Línea con los Plazos Previstos .
10 octubre 2012
Lurbinectedin ( PharmaMar ) . New Animal Models can Revolutionize the Study of Cancer .
Some animal models developed by researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL) and the Catalan Institute of Oncology (ICO) has served to validate the effectiveness of a new drug against ovarian cancer resistant to cisplatin. The multidisciplinary work, done in collaboration with the biopharmaceutical company Pharmamar, was published in the journal Clinical Cancer Research. ...
Doxil , J&J Ya ha Pedido a la FDA y a la EMEA una Aprobación para Fabricar de Nuevo el Farmaco .
... Now, J&J wants to enlist Ben Venue's help again. As The Wall Street Journal reports, J&J's new Doxil plan would rely on Ben Venue to produce the drug, in areas of its Bedford plant that are now available and approved for use. Another supplier would handle sterile filtration and aseptic filling, to make sure the drug isn't contaminated.
J&J has asked FDA and its counterparts in the EU to approve the new process, the WSJ says. That would amp up Doxil supplies in the short term, giving J&J time to find a long-term manufacturer for Doxil.
J&J has asked FDA and its counterparts in the EU to approve the new process, the WSJ says. That would amp up Doxil supplies in the short term, giving J&J time to find a long-term manufacturer for Doxil.
Suscribirse a:
Comentarios (Atom)